DNA Synthesis Market - By Service (Oligonucleotide Synthesis, Gene Synthesis), Method (Solid Phase, PCR-based, Chip-based), Application (Research & Development, Diagnostics, Therapeutic), End-use (Biopharmaceutical, CRO), Global Forecast 2024 – 2032

DNA Synthesis Market Size

DNA Synthesis Market size was valued at USD 4 billion in 2023 and is projected to witness growth at a CAGR of 18.9% between 2024 and 2032. High market growth can be attributed to the advancements in synthetic biology and gene editing technologies such as CRISPR, coupled with growing adoption of precision medicine.
 

The growing emphasis on synthetic biology research is primarily driven by robust support for DNA synthesis initiatives, marked by substantial investments in R&D, alongside an expanding focus on DNA studies. For instance, in April 2023, NunaBio, a TechBio company specializing in synthetic DNA for research, secured USD 2.4 million in a seed round, supported by the Northeast Innovation Fund and the European Regional Development Fund.
 

The company is focused on innovating a groundbreaking approach to DNA synthesis, facilitating the efficient and cost-effective production of oligonucleotides on a large scale, with remarkable speed and precision. Thus, such growing research funding aimed to support and catalyze the development of technology, fosters the potential of synthetic biology across the genome sector, thereby propelling the market growth.
 

DNA synthesis is the process of artificially creating DNA molecules. It involves chemically synthesizing nucleotide sequences in the laboratory, that can be used for various applications such as genetic engineering, research, and biotechnology.
 

DNA Synthesis Market Trends

• Growing investments in biotechnology and life sciences research, propelled by government grants, private funding, and venture capital, has led to a surge in demand for DNA synthesis services and products.
   
• In addition, companies and academic institutions are increasingly allocating resources to R&D activities aimed at advancing DNA synthesis technologies and applications, buoyed by the recognition of DNA synthesis as a fundamental tool across various fields further propelling the market growth.
   
• For instance, in 2021, Molecular Assemblies received USD 25.8 million funding from Casdin Capital to enhance enzymatic DNA synthesis technology. Similarly, In March 2021, Twist Bioscience announced a USD 100 million private placement investment from several investors, including Casdin Capital, Fidelity Management & Research Company, and Viking Global Investors to advance their DNA synthesis platform.
   
• Thus, the expansion of R&D investment is anticipated to continue driving the growth of the market, fostering innovation and addressing emerging challenges in diverse industries.
   

DNA Synthesis Market Analysis

Based on service, the market is segmented into oligonucleotide synthesis and gene synthesis. The oligonucleotide synthesis segment is further divided into standard oligonucleotide synthesis and custom oligonucleotide synthesis. Oligonucleotide synthesis segment dominated the market in 2023 with a market share of 58%.
 

• The oligonucleotide synthesis segment holds a significant market share in the market due to its crucial role in various applications, including genetic testing, molecular diagnostics, synthetic biology, and gene editing.
   
• Oligonucleotides are synthesized with specific base pairs using nucleotide strands, serve primarily as primers and probes in biological processes. The synthesis technique offers a swift and cost-effective means to produce desired sequences witnessing its higher demand.
   
• Moreover, advancements in technology, such as automated synthesizers and high-throughput platforms, are further fueling the market's expansion by enhancing the efficiency and scalability of oligonucleotide synthesis
   

Based on method, the DNA synthesis market is segmented into solid-phase synthesis, PCR-based enzyme synthesis, and chip-based synthesis. The solid-phase synthesis segment accounted for significant market share in 2023 and is poised to capture the market size of USD 9 billion by 2032.
 

• The dominance of solid-phase synthesis arises from its efficiency and versatility in constructing DNA sequences on solid supports, facilitating step-by-step nucleotide addition. Also, its controlled, automated nature ensures precise oligonucleotide synthesis, minimizing errors and maximizing yield, appealing to the market.
   
• Furthermore, high scalability and cost-effectiveness of solid-phase synthesis method makes it favourable for both research and industrial applications, establishing it as the preferred method for custom DNA production across diverse sectors, solidifying its dominance in the market.
   

Based on application, the DNA synthesis market is segmented into research and development, diagnostics, and therapeutics. The research and development segment dominated the market in 2023 and is anticipated to grow at a CAGR of 19.3% over the analysis period.
 

• Research and development hold a significant market share in the market due to its crucial role in advancing biotechnology and pharmaceutical research. This segment encompasses activities aimed at developing new DNA synthesis techniques, enhancing existing methodologies, and exploring novel applications of synthetic DNA.
   
• Further, the growing demand for custom DNA sequences for experimental studies, drug discovery, and genetic engineering purposes fuels the growth of DNA synthesis. For instance, according to SynBioBeta, the global bio-engineering sector utilizes over 3 kg of nucleotide bases annually for diverse research purposes. Therefore, the increasing adoption of nucleotides reflected a rising emphasis on DNA research.
   
• Thus, as the demand for customized DNA sequences for various research purposes grows, the research and development segment is poised to maintain its high market share by continually pushing the boundaries of what is possible in synthetic biology.
   

Based on end use, the DNA synthesis market is segmented into biopharmaceutical companies, academic & research institutes, and contract research organizations. Biopharmaceutical companies’ segment is anticipated to growth at a CAGR of 18.4% between 2024 – 2032.
 

• This growth is driven by the increasing demand for personalized medicine, where DNA synthesis plays a critical role in creating customized treatments tailored to individual patients' genetic makeup.
   
• Biopharmaceutical companies are increasingly investing in DNA synthesis technologies to accelerate drug discovery and development processes, leading to the creation of novel therapies for various diseases.  Therefore, as these companies continue to innovate and collaborate with research institutions, the biopharmaceutical companies’ segment is expected to experience significant growth in the coming years.
   
• Additionally, the rising prevalence of genetic disorders and the expanding applications of DNA synthesis in gene editing and gene therapy further contribute to the segment's growth potential.
   

North America dominated the global DNA synthesis market in 2023 with a market share of 36.5% and is anticipated to grow at a CAGR of 18.4% over the analysis period.
 

• The region’s robust R&D infrastructure, coupled with concentration of key players and leading research institutions specializing in synthetic biology and gene editing technologies contribute to the region’s dominance in the genome field.
   
• For instance, increasing research funding and strategic initiatives by key players has stimulated studies aimed at addressing the demand for effective treatments for chronic diseases. In April 2021, DNAScript partnered with Moderna, along with USD 5 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA). This collaboration aimed in creating a prototype for the efficient manufacturing of therapeutics and vaccines, as part of the global nucleic acids on-demand program.
   
• Such initiatives highlight the region's leadership in fostering partnerships between innovative companies and government agencies, aimed in advancing DNA synthesis technologies for critical healthcare solutions.
   

The U.S. DNA synthesis market is anticipated to grow at a CAGR of 18.3% between 2024 – 2032.
 

• The country's well-established regulatory framework and supportive government policies further contribute to market growth, facilitating innovation and commercialization of DNA synthesis technologies.
   
• Additionally, the high demand for synthetic DNA in various applications such as genetic engineering, drug development, and personalized medicine drives the market.
   
• The extensive adoption of DNA synthesis in academic and industrial research, coupled with a robust supply chain and distribution network, solidifies the U.S. as a key player in the market.
   

Europe DNA synthesis market was valued at USD 1.1 billion in 2023 and is projected to reach USD 5.3 billion by 2032.
 

• Europe is home to many pharmaceutical and biotechnology companies, which are major consumers of synthetic DNA for drug discovery, development, and manufacturing purposes. These companies often require custom-designed DNA sequences for various applications, including protein expression, gene editing, and molecular diagnostics, driving the demand for DNA synthesis services.
   
• Secondly, Europe has a strong academic and research infrastructure, with renowned universities and research institutes conducting cutting-edge research in genomics, synthetic biology, and related fields. This research generates a constant demand for synthetic DNA for experimental purposes, further boosting the market.
   

Asia Pacific region is anticipated to witness high growth in DNA synthesis market, growing at a CAGR of 19.6% over the analysis years.
 

• The region is witnessing a significant increase in research and development activities, particularly in the fields of biotechnology, pharmaceuticals, and genetic engineering. This surge is fuelled by a growing emphasis on precision medicine, personalized healthcare, and advancements in synthetic biology.
   
• Additionally, a rising prevalence of diseases in the region is driving the need for genetic testing and personalized medicine. This trend is leading to increased demand for custom DNA synthesis services, further fuelling market growth.
   

DNA Synthesis Market Share

The market is characterized by a diverse array of companies offering a range of synthesis services and technologies. Key players in this market such as Thermo Fisher Scientific Inc., Eurofins Scientific, GenScript Biotech Corporation, Integrated DNA Technologies, and Quintara Biosciences are dominating the market with their comprehensive service offerings, advanced technologies, and global presence. Additionally, startups like Synbio Technologies and Twist Bioscience are disrupting the market with novel synthesis platforms and rapid DNA assembly techniques. Partnerships and collaborations between industry players and academic institutions are common, fostering innovation and driving the development of cutting-edge solutions. Factors such as technological advancements, regulatory landscape, and strategic alliances continue to shape the competitive dynamics of the market.
 

DNA Synthesis Market Companies

Prominent players operating in the DNA synthesis industry include:

• BIOMATIK
• Bioneer Corporation
• Eton Bioscience, Inc.
• Eurofins Scientific
• GenScript Biotech Corporation
• IBA Lifesciences GmbH
• Integrated DNA Technologies, Inc.
• Kaneka Eurogentec S.A.
• LGC Biosearch Technologies
• OriGene Technologies, Inc.
• ProMab Biotechnologies, Inc.
• ProteoGenix
• Quintara Biosciences
• Synbio Technologies
• Thermo Fisher Scientific Inc.
• Twist Bioscience Corporation
   

DNA Synthesis Industry News:

• In May 2023, GenScript Biotech Corporation introduced GenTitan gene fragments synthesis service, the world's first and only commercial miniature semiconductor platform utilizing integrated circuits for high-throughput DNA synthesis. This launch helped the company to broaden their offerings and enhance their revenue growth.
   
• In November 2021, GeneScript announced expansion of commercial production facility for highly automated gene synthesis and plasmid preparation services near its U.S. headquarters in Piscataway, New Jersey. This expansion helped the company to expand its geographic reach and customer base.
   
• In November 2021, Telesis Bio, Inc. announced the acquisition of Eton Bioscience, a privately held provider of synthetic biology products and services. This acquisition helped the company to strengthen brand and expand its market reach.
   

The DNA synthesis market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Service

• Oligonucleotide synthesis
  • Standard oligonucleotide synthesis
  • Custom oligonucleotide synthesis
• Gene synthesis
  • Custom gene synthesis
  • Gene library synthesis

Market, By Method

• Solid-phase synthesis
• PCR-based enzyme synthesis
• Chip-based synthesis

Market, By Application

• Research and development
• Diagnostics
• Therapeutics

Market, By End-use

• Biopharmaceutical companies
• Academic & research institutes
• Contract research organizations

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa